Literature DB >> 114652

Effect of chrysotherapy on parameters of immune response.

A Lorber, T M Simon, J Leeb, A Peter, S A Wilcox.   

Abstract

Thirty-nine subjects with classical or definite rheumatoid arthritis received weekly intramuscular gold sodium thiomalate (GST) to sustain gold blood levels of more than 320 microgram/dl. Statistical analysis revealed significant declines from pre-treatment values for IgM, IgG, and IaA. Rheumatoid factor titer decreased in 29 of 39 subjects, 15 becoming seronegative. Circulating lymphocytes decreased by 27%. The maximal suppressive effect on IgM was not achieved until the 3rd and 4th years of GST administration. Auranofin (AF) 6 mg/day was administered to 15 patients for an average interval of 45 weeks. In vitro and in vivo suppression of lymphocyte mitogen response with AF was more rapid in onset and significantly greater than with GST. Suppression of dinitrochlorobenzene skin sensitization was observed in AF patients. The clinical response in GST treated subjects correlated with suppression of immunoglobulins, rheumatoid factor titer, and circulating lymphocytes. A significant decline in these variables was not achieved for a corresponding interval with AF treatment. It is suggested that chrysotherapy may be applied more widely to immunologically-mediated disorders and perhaps be used to affect selectively B versus T mediated dysfunction.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 114652

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  6 in total

Review 1.  Clinical pharmacokinetics of oral and injectable gold compounds.

Authors:  K L Blocka; H E Paulus; D E Furst
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

2.  Flow cytometry enables a high-throughput homogeneous fluorescent antibody-binding assay for cytotoxic T cell lytic granule exocytosis.

Authors:  Amy E Florian; Christopher K Lepensky; Ohyun Kwon; Mark K Haynes; Larry A Sklar; Adam Zweifach
Journal:  J Biomol Screen       Date:  2012-11-15

Review 3.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

4.  Serum biochemistry in relation to the action of azathioprine in rheumatoid arthritis.

Authors:  J S Dixon; H A Bird; N G Sitton; M E Pickup; P A Leatham; V Wright
Journal:  Agents Actions       Date:  1983-06

5.  Changes in immune function in patients with rheumatoid arthritis following treatment with sodium aurothiomalate.

Authors:  J Highton; G S Panayi; P Shepherd; J Griffin; T Gibson
Journal:  Ann Rheum Dis       Date:  1981-06       Impact factor: 19.103

6.  Effect of auranofin on antibody-dependent cellular cytotoxicity (ADCC) mediated by rat peripheral blood polymorphonuclear leukocytes and mononuclear cells.

Authors:  M J DiMartino; D T Walz
Journal:  Inflammation       Date:  1980-09       Impact factor: 4.092

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.